PD-L1 NSCLC market report provides current treatment practices, emerging drugs, PD-L1 NSCLC market share of the individual therapies, current and forecasted PD-L1 NSCLC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current PD-L1 NSCLC treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Key Highlights from PD-L1 NSCLC market report:-
- Programmed death-ligand 1 (PD-L1) mutated NSCLC total cases in 7MM in 2017 was 242,014
- Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States was 89,597 in 2017.
- Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was 11,585.
- The total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in EU5 countries in 2017 were
- Germany – 28,509 cases
- France – 20,110 cases
- Italy – 17,021 cases
- Spain – 11,585 cases
- The United Kingdom –22,192 cases
Scope of the Report
• The report covers the descriptive overview of PD-L1 NSCLC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into thePD-L1 NSCLC epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for PD-L1 NSCLC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of PD-L1 NSCLC market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PD-L1 NSCLC market.
Programmed death-ligand 1 (PD-L1) mutated NSCLC market size in 7MM was USD 6,536 million in 2017.
PD-L1 NSCLC Market Drivers
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity
- Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC
PD-L1 NSCLC Market Barriers
- Cost-Effectiveness of Therapies
- Cost of Therapies
- Burden of Disease
PD-L1 NSCLC Treatment
PD-1/PD-L1 blocking antibodies therapy is recommended for the patients showing PD-L1 expressions. In recent years, immunotherapy has revolutionized and changed the standard of care in patients with NSCLC. Immune checkpoint inhibitors, fundamentally those that act by blocking PD-1 and its ligand, the PD-L1, have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy.
Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as Opdivo (nivolumab), Tecentriq (atezolizumab), Keytruda (pembrolizumab, and recently, Imfinzi (durvalumab). Among all of the approved PD-1/PD-L1 inhibitors, the NSCLC therapy area is dominated by Keytruda (pembrolizumab), with revenues from this particular market helping the drug to achieve a hit status.
Table of contents
1. Key Insights
2. Executive Summary of PD-L1 NSCLC
3. SWOT Analysis of PD-L1 NSCLC
4. PD-L1 NSCLC Market Overview at a Glance
4.1. Total Market Share (%) Distribution of PD-L1 NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of PD-L1 NSCLC in 2030: By Country
5. PD-L1 Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of PD-L1 NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total PD-L1 NSCLC cases in the United States
7.4.5. Total PD-L1 NSCLC Treated patient Pool in the United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total PD-L1 NSCLC cases in Germany
8.1.5. Total PD-L1 NSCLC Treated patient Pool in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total PD-L1 NSCLC cases in France
8.2.5. Total PD-L1 NSCLC Treated patient Pool in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total PD-L1 NSCLC cases in Italy
8.3.5. Total PD-L1 NSCLC Treated patient Pool in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total PD-L1 NSCLC cases in Spain
8.4.5. Total PD-L1 NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total PD-L1 NSCLC cases in the United Kingdom
8.5.5. Total PD-L1 NSCLC Treated patient Pool in the United Kingdom
9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total PD-L1 NSCLC cases in Japan
9.1.5. Total PD-L1 NSCLC Treated patient Pool in Japan
10. Current Treatment Practices: PD-L1 NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of PD-L1 NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. PD-L1 NSCLC Marketed Therapies
14.1. Key Cross
14.2. Imfinzi (Durvalumab): AstraZeneca
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.2.6. Safety and Efficacy of Ongoing Clinical Trials
14.3. Opdivo (Nivolumab): Bristol-Myers Squibb
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity
14.4. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Other Developmental Activities
14.4.4. Pivotal Clinical Trials
14.4.5. Ongoing Current Pipeline Activity
14.5. Keytruda (Pembrolizumab): Merck
14.5.1. Product Description
14.5.2. Regulatory Milestones
14.5.3. Other Developmental Activities
14.5.4. Pivotal Clinical Trials
14.5.5. Ongoing Current Pipeline Activity
15. Emerging Therapies
15.1. Canakinumab (ACZ885): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.2. Avelumab (Bavencio): Merck KGaA and Pfizer
15.2.1. Product Description
15.2.2. Clinical Development
15.2.3. Safety and Efficacy
15.3. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.3.1. Product Description
15.3.2. Clinical Development
15.3.3. Safety and Efficacy
15.4. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Safety and Efficacy
16. PD-L1Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
16.1. Key Findings
16.2. Market Outlook: 7MM
17. PD-L1—Market Size
17.1. Total Market Size of PD-L1 NSCLC in the 7MM
17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of PD-L1 NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of PD-L1 NSCLC in Japan
18. Market Access and Reimbursement of PD-L1 NSCLC Therapies
19. PD-L1 NSCLC Market Drivers
20. PD-L1 NSCLC Market Barriers
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/